Mother's Milk is Best

New Haven, Connecticut

OncologyPhase I

Compare Sign in to watch

What changed

NIH R01 · $0.8M · Defining the role for polyamines in cholestatic liver disease

6w agoNew grantJun 4, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,208 pre-ticker oncology companies at Phase I

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Sep 1, 2026
Preterm Infant Health, Premature Babies · NOT_YET_RECRUITING · sponsor: Mother's Milk is Best · Human Milk Concentrating Device to Optimize Mother's Own Milk
ClinicalTrials.gov · NCT07576972 (opens the source filing in a new tab)
Grant
R01 · $775k · non-dilutive
Jun 15, 2026
UNIVERSITY OF COLORADO DENVER · PI TAYLOR, SARAH ANN · NIDDK · award ends Feb 28, 2031 · Defining the role for polyamines in cholestatic liver disease
NIH RePORTER · NIH RePORTER 11339647 (opens the source filing in a new tab)
Trial
PHASE1 registered
Sep 18, 2019
Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7 · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
ClinicalTrials.gov · NCT02595879 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator TAYLOR, SARAH ANN is named on this company's filings
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Sarah Ann Taylor

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.8M · Defining the role for polyamines in cholestatic liver disease
6w agoNew grantSource (opens the source filing in a new tab)
Phase I trial registered: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
7w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Human Milk Concentrating Device to Optimize Mother's Own Milk
2mo agoTrial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

NA registered

R01 · $775k · non-dilutive

PHASE1 registered